Theriva Biologics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Theriva Biologics amended and restated the employment agreement for Steven A. Shallcross, effective August 10, 2026, replacing his March 3, 2025 agreement. Shallcross continues as President, CEO, and CFO with a base salary of $687,562 annually, eligibility for up to 50% annual bonus, 243,205 vested/unvested stock options, and two-year employment term. Severance upon termination without Cause includes 12 months base salary continuation plus COBRA; Change in Control triggers 2× (base + target bonus) plus 24 months COBRA premium equivalents, plus $500,000 non-compete payment.
Why this rating
Standard executive renewal; modest base salary (~18% of $3.9M market cap) and severance obligations are material but routine governance. No business change indicated.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.